Hls Therapeutics Inc (HLS-T) Stock Price and News - The Globe and Mail

Add to Watchlist Create Alerts

Real-Time Last Update

Volume

Day Low4.60

Day High4.95

Open:4.95

Previous Close

52-Week High/Low

Volume

Average Volume

Price/Earnings (TTM)

Forward Annual Dividend & Yield

Market Capitalization, $M

5-Day Change

Automated Summaries - The Globe and Mail

Closing Bell: Hls Therapeutics Inc down on Monday (HLS)

Stocks in play: HLS Therapeutics Inc.

HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

HLS Therapeutics Announces Fiscal 2023 Financial Results

HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call

February 29, 2024

HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan

February 6, 2024

HLS Therapeutics Announces CFO Departure

December 18, 2023

New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

November 14, 2023

HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid

November 9, 2023

HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call

October 26, 2023

Stocks in play: HLS Therapeutics Inc.

September 6, 2023

HLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment Conference

September 6, 2023

AI-generated - The Globe and Mail

HLS Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (HLS)

August 22, 2023

HLS Therapeutics Announces Updates to its Credit Agreement

August 14, 2023

HLS Therapeutics Announces Q2 Fiscal 2023 Financial Results

August 10, 2023

HLS Therapeutics to Host Q2 Fiscal 2023 Financial Results Conference Call

Stocks in play: HLS Therapeutics Inc.

HLS Therapeutics Announces Updates to its Board of Directors

HLS Therapeutics Reports Annual Meeting Results

HLS Therapeutics Announces Agreement with Polar Asset Management Partners and Retirement of Two Directors from the Board of Directors

The Globe and Mail

HLS Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (HLS)

HLS Therapeutics Announces Q1 Fiscal 2023 Financial Results

Stocks in play: HLS Therapeutics Inc.

HLS Therapeutics to Host Q1 Fiscal 2023 Financial Results Conference Call

The Globe and Mail

HLS Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (HLS)

Stocks in play: HLS Therapeutics Inc.

HLS Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

HLS Therapeutics Announces CEO Transition

The Globe and Mail

HLS Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (HLS)

Stocks in play: HLS Therapeutics Inc.

HLS Therapeutics Announces Q4 and Fiscal 2022 Financial Results

Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, and the United States, and the Rest of the world.